Increased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas

Basit Öğe Kaydı
dc.contributor.authorDogan, B. A.
dc.contributor.authorTuna, M. M.
dc.contributor.authorArduc, A.
dc.contributor.authorBasaran, M. N.
dc.contributor.authorKucukler, K.
dc.contributor.authorDagdelen, I.
dc.contributor.authorBerker, D.
dc.date.accessioned2024-04-24T16:24:09Z
dc.date.available2024-04-24T16:24:09Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe aim of this study was to investigate atherosclerotic risk markers in women with clinically nonfunctioning pituitary adenomas (CNFAs). Records of 47 women with CNFAs and 73 healthy women who were treated as outpatients between January 2010 and March 2014 were evaluated retrospectively. All study data were obtained from file records. Lipid parameters, mean platelet volume (MPV), total testosterone (TT), androstenedione (AS), and dehydroepiandrostenedione sulfate (DHEAS) were recorded. Insulin resistance (IR) was calculated with homeostatic model assessment-insulin resistance (HOMA-IR). Among the atherosclerotic risk markers, the HOMA-IR and AS levels were higher in patients with CNFAs than in healthy subjects (p=0.003, p=0.021, respectively). A positive correlation between AS and insulin/HOMA-IR levels was found among the metabolic parameters in the patients with CNFAs (p=0.001, r=0.550, p=0.004, r=0.498, respectively). The data showed that patients with CNFAs had high atherosclerotic risk markers such as insulin resistance and hyperandrogenemia. Insulin resistance may also cause hyperandrogenemia in patients with CNFAs.en_US
dc.identifier.doi10.1055/s-0035-1547234
dc.identifier.endpage655en_US
dc.identifier.issn0018-5043
dc.identifier.issn1439-4286
dc.identifier.issue9en_US
dc.identifier.pmid25750077
dc.identifier.scopus2-s2.0-84938747240
dc.identifier.scopusqualityQ2
dc.identifier.startpage652en_US
dc.identifier.urihttps://doi.org/10.1055/s-0035-1547234
dc.identifier.urihttps://hdl.handle.net/11468/16536
dc.identifier.volume47en_US
dc.identifier.wosWOS:000359597300005
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherGeorg Thieme Verlag Kgen_US
dc.relation.ispartofHormone and Metabolic Research
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAndrogensen_US
dc.subjectAtherosclerotic Risk Markersen_US
dc.subjectClinically Nonfunctioning Pituitary Adenomasen_US
dc.titleIncreased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomasen_US
dc.titleIncreased Risk of Unfavorable Metabolic Outcome in Patients with Clinically Nonfunctioning Pituitary Adenomas
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu